In December 2014, the U.S. Food and Drug Administration (FDA) granted olaparib accelerated approval for monotherapy in patients with germline BRCA1/2 mutations and recurrent ovarian cancer with three or more prior lines of chemotherapy, making olaparib the first of the PARP inhibitors to receive FDA approval. Here, BRCA1 is linked to ovarian cancer.